Immatics Reports Q1 2026 Results, Highlights Key Clinical Milestones & Extends Cash Runway

summarizeSummary

Immatics N.V. reported an increased net loss in Q1 2026 but confirmed a strong cash runway into 2028 and outlined critical upcoming clinical milestones for its PRAME franchise, including Phase 3 data for anzu-cel in 2026.

check_boxKey Events

• Q1 2026 Financial Results

  Net loss increased to €57.8 million for Q1 2026, up from €39.9 million in Q1 2025, driven by higher research and development expenses as clinical trials advance.

• Extended Cash Runway

  Cash and other financial assets totaled €453.6 million as of March 31, 2026, with a projected cash reach into 2028, providing a solid financial foundation for ongoing operations.

• Phase 3 Trial Progress for Anzu-cel

  Interim and final data analyses for the Phase 3 SUPRAME trial of anzu-cel (PRAME cell therapy) are expected to be triggered in 2026, with BLA submission targeted for H1 2027 and commercial launch in H2 2027.

• Multiple Upcoming Clinical Data & Trials

  Several key clinical data readouts are expected in 2026 across the PRAME franchise, including for IMA203CD8 and IMA402, and a new Phase 1 combination trial for IMA401/IMA402 bispecifics is set to begin mid-2026.

auto_awesomeAnalysis

Immatics N.V. reported an increased net loss for Q1 2026, primarily due to higher research and development expenses as it advances its clinical pipeline. However, the company maintains a strong cash position, projected to fund operations into 2028, which is critical for a clinical-stage biotech. The filing provides a clear roadmap of significant upcoming clinical milestones, including the anticipated Phase 3 data trigger for its lead PRAME cell therapy, anzu-cel, in 2026, and plans for BLA submission and commercial launch in 2027. These clinical catalysts are key drivers for future valuation.